Amylyx Pharmaceuticals annual current ratio
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Current Ratio Growth & History (AMLX)
Amylyx Pharmaceuticals's current ratio was 14.27 for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 14.27 | 7.60 | +113.93% |
| 2024 | 2024-12-31 | 6.67 | 1.00 | +17.74% |
| 2023 | 2023-12-31 | 5.66 | −2.53 | −30.92% |
| 2022 | 2022-12-31 | 8.20 | 2.17 | +35.90% |
| 2021 | 2021-12-31 | 6.03 | — | — |
Amylyx Pharmaceuticals quarterly current ratio
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.12 | 3.40 | +38.94% |
| Q1 2026 | 2026-03-31 | 17.85 | 5.80 | +48.11% |
| Q4 2025 | 2025-12-31 | 14.27 | 7.60 | +113.93% |
| Q3 2025 | 2025-09-30 | 13.70 | 9.15 | +201.20% |
| Q2 2025 | 2025-06-30 | 8.72 | 4.06 | +87.11% |
| Q1 2025 | 2025-03-31 | 12.05 | 7.57 | +169.06% |
| Q4 2024 | 2024-12-31 | 6.67 | 1.00 | +17.74% |
| Q3 2024 | 2024-09-30 | 4.55 | −4.97 | −52.20% |
| Q2 2024 | 2024-06-30 | 4.66 | −2.01 | −30.10% |
| Q1 2024 | 2024-03-31 | 4.48 | −3.06 | −40.56% |
| Q4 2023 | 2023-12-31 | 5.66 | −2.53 | −30.92% |
| Q3 2023 | 2023-09-30 | 9.52 | 4.24 | +80.42% |
| Q2 2023 | 2023-06-30 | 6.67 | −1.29 | −16.18% |
| Q1 2023 | 2023-03-31 | 7.54 | −2.04 | −21.34% |
| Q4 2022 | 2022-12-31 | 8.20 | 2.17 | +35.90% |
| Q3 2022 | 2022-09-30 | 5.27 | — | — |
| Q2 2022 | 2022-06-30 | 7.96 | — | — |
| Q1 2022 | 2022-03-31 | 9.58 | — | — |
| Q4 2021 | 2021-12-31 | 6.03 | — | — |
Amylyx Pharmaceuticals current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's current ratio increased from 6.03 to 14.27, a change of 8.23. The latest reported quarter, Q2 2026, shows 12.12.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗